Other languages Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Market Closed - Nasdaq Other stock markets 21:00:00 21/06/2024 BST			5-day change	1st Jan Change
3.63 ^USD	+1.97%		-5.22%	-35.75%

06-14	Monte Rosa Therapeutics, Inc. Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis	CI
05-30	Monte Rosa Therapeutics Names Three Insiders to Leadership Team	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Monte Rosa Therapeutics, Inc. Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis	06-14
Monte Rosa Therapeutics, Inc. Announces Executive Promotions	05-30
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	05-16
Monte Rosa Therapeutics Prices $100 Million Public Offering	05-16
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09
Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board	05-02
Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline	03-14
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14
Monte Rosa Therapeutics, Inc. Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1b Pathway Inhibitor	03-11
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Monte Rosa Therapeutics Partners With Roche in Targeting Cancer, Neurological Diseases; Shares Surge Pre-Bell	17/10/23
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors	17/10/23
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases	17/10/23
Monte Rosa Says on Track to File Application for Autoimmune Diseases Treatment, Provide Initial Data on Solid Tumors Therapy	10/08/23
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23
Monte Rosa Therapeutics, Inc. Appoints Anthony M. Manning to the Board of Directors	26/07/23
Monte Rosa Therapeutics Advances Second Development Candidate	23/05/23
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, A Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases	23/05/23
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23
Monte Rosa Therapeutics, Inc. Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023	17/04/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Other languages

Filters